cutaneous Squamous Cell Carcinoma (cSCC) Network

Follow us for the latest research updates of cutaneous squamous cell carcinoma #metastasis #cSCC #cell #Therapeutic #squamous #skin #cancer #media #cutaneous

[JAMA+ AI @JAMAplusAI]

This @JAMADerm editorial discusses a novel risk stratification system for cutaneous squamous cell carcinoma that was developed using a retrieval augmented generation–enabled large language model.

https://t.co/Tk0O7CzUmy

[cutaneous Squamous Cell Carcinoma (cSCC) Network @SquamousCscc]

Role of CTCF in #cscc progression

[Amarinder @amarinder_thind]

🚨 New preprint!
CTCF Binding Site Mutations: Linking TAD Dysregulation to cSCC Progression
We show how mutations at CTCF sites drive metastasis in skin cancer.
🧬📊

#Genomics #CTCF #3Dgenome #cSCC #Bioinformatics #Cancer #nswheath

https://t.co/DmAVFvbkET

[JAMA Oncology @JAMAOnc]

Most viewed this week from @JAMAOnc:

ICIs can treat advanced cancers in solid organ transplant recipients, especially cSCC, but overall survival is limited, and mTOR inhibitors with steroids may reduce rejection risk.

https://t.co/CrNWmHptbv

[Dermal Cell News @DermalCell]

An in-depth look at the involvement of kindlin-1 in cutaneous squamous cell carcinoma (SCC). 👀

Drs. Carrasco, Brunton, and colleagues at @EdinCRC provide evidence that Kindlin-1 loss 🚫 in SCC can promote invasion through the upregulation of MMP13.

🔗 https://t.co/qSNQr1WHZx

[AHNS @AHNSinfo]

New Post! Thank you to Dr. Michael Baddour, Head & Neck Surgeon at Emory University, who composed this expert review of the importance of understanding perineural spread in cutaneous squamous cell carcinomas of the head and neck. #AHNSSkin @AHNSinfo
https://t.co/gGorb2A8NY

[Joe @Gantosj]

What differentiate $MDNAF from other #IL2 is "Durability"

Many are asking me, why $HOWL is down so much despite the CR they had in Cutaneous SCC?

So I went back to $HOWL slides & looking deeper into the slide while focusing ONLY on the high dose (disregard all the lower dose from dose escalation) we can see the 2 PR's patients went back to "Progressive Disease" 8 weeks from getting PR!

Many patients on the high dose >12mg/kg progressed after 8 - 16 weeks!

On the other hand, $MDNA.to show that all patients who had a clinical activity had a longer period of time on the drug, including a 2 years PDAC patient 100% free!

[Foster Drug Info⚕️ @FosterDrugInfo]

⚠️#Hydrochlorothiazide: #cutaneous_squamous_cell_carcinoma (SCC)

☀️In a case-control study, Hydrochlorothiazide users had a 2- to 7-fold increased risk of cutaneous #SCC, with a clear dose-response effect.

😎Patient education on #Sun_avoidance & #Sun_protection is recommended.

[Bruce Ashford @drbruceashford]

Very valuable overview and interrogation of data. Great work Lee Lab! @Stanford @StanfordMed
@BencomoTomas @CarolynLeeMDPhD Gene expression landscape of cutaneous squamous cell carcinoma progression https://t.co/9PYKP5PZC7

[Bruce Ashford @drbruceashford]

@mranson2 @cbioportal @amarinder_thind @DrGopalIyer @jcBeyond5 @GuptaRuta Our first 25 metastatic cSCC WGS 90X/30X.
Plenty to explore including clinical data.
Thanks again to our generous patients who allowed us access to their tumours.

[fuckyoucancer.sats|ᛤ|🐕|BitmapEmporium 🟧 @GlennLichtenbe2]

Hey mate, this is awesome. I am a B.I. Administrator, with a broad experience in IT from dev/coding to testing to DB work. Happy to discuss offline. :-) I am also currently battling stage 4 metastatic cutaneous scc. I am doing what I can where I can to fight it. Or help out where I can. The only thing holding back the cancer inside my body is an experimental drug where I am part of a clinical trial. Again, happy to discuss offline. Please DM me, Many thanks in advance, mate! 🙏🙏

[cutaneous Squamous Cell Carcinoma (cSCC) Network @SquamousCscc]

Limitations of the Commercially Available Gene Expression Test in Predicting Cutaneous Squamous Cell Carcinoma Metastasis and Clinical Outcomes - Journal of the American Academy of Dermatology https://t.co/LxUHhBvmo2

[BJD @BrJDermatol]

With the advent of RNA-based medicine, PVT1 may be a promising molecular target for the management of inoperable or metastatic cutaneous squamous cell carcinoma (cSCC). Increased expression of PVT1 may serve as a biomarker for cSCCs.

https://t.co/2zjXsrv5Xr

[cutaneous Squamous Cell Carcinoma (cSCC) Network @SquamousCscc]

Extrachromosomal DNA in cutaneous squamous cell carcinoma is associated with increased nodal disease https://t.co/rDjs7w7twn

[Tomas Bencomo @BencomoTomas]

My 1st first author preprint is out! @CarolynLeeMDPhD and I analyzed public RNA-Seq data from 147 cutaneous squamous cell carcinoma (cSCC) samples to create a set of robust differentially expressed genes (DEGs) involved in cSCC pathogenesis

https://t.co/reJDiIk3NE

🧵 below! /1

[DelveInsight @delve_insight]

Expected changes in the Cutaneous Squamous Cell Carcinoma (cSCC) market are driven by improved diagnostics, heightened disease awareness, & upcoming therapy introductions.

Learn more about the key factors that profoundly alter the cSCC market dynamics: https://t.co/gNNRmCPEVs.

[cutaneous Squamous Cell Carcinoma (cSCC) Network @SquamousCscc]

PI3K and CDK inhibitors combo against advanced cutaneous squamous cell carcinoma. https://t.co/ZuyXbMmBgF

[Amarinder @amarinder_thind]

🔬✨Dynamic dance of PI3K and CDK inhibitors against advanced cSCC. @DrJayPerry 🩸🔍 combos show promise, but the road to perfection lies in matching drug specifics to individual mutations. 🧬💊 #CancerResearch #SkinHealth 🌞👩‍🔬

[Neil D. Gross, MD, FACS @DrNeilGross]

Heading in to #ESMO23 ☀️ 😎 to present updated survival results for the phase 2 trial of #neoadjuvant #immunotherapy in resectable cutaneous #squamous #skin #cancer #cSCC @SquamousCscc @NEJM @AHNSinfo @Regeneron @MDAndersonNews

[Oncogene Journal @oncogenejournal]

Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic #SkinCancer with high mortality rates. @ElinaSiljamaki et al. identify PLX8394 as a potential therapeutic compound for advanced and metastatic cSCC.

👉https://t.co/jjdRyIYdQs

[Journal for ImmunoTherapy of Cancer @jitcancer]

PD-1-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) ineligible for surgery or radiation. But some patients don’t respond or have severe immune-related adverse events. There is a need for improved therapies. 2/11

[Prof. Kähäri Research Group @KahariLab]

Glad to share our collaborative paper with the group of [email protected] on lncRNA PVT1 in cSCC

Long non-coding RNA PVT1 is overexpressed in cutaneous squamous cell carcinoma and exon 2 is critical for its oncogenicity https://t.co/MK3VEruTPt